Chardan Initiates Coverage of Monopar Therapeutics (MNPR) Stock, Gives Buy

Monopar Therapeutics Inc. (NASDAQ:MNPR) is one of the 10 Unstoppable Stocks to Buy According to Hedge Funds. On June 23, Chardan analyst Keay Nakae began coverage of the company’s stock with a “Buy” rating and a price objective of $60, as reported by The Fly. The firm cited potential in its late-stage Wilson disease treatment as well as an early-stage radiopharmaceutical pipeline for the rating. In the research note, the analyst mentioned that the company’s co-founder and Chief Executive Officer has a long history with the development of ALXN1840.

Close-up of a scientist using a microscope to study a sample, as part of a research project related to cancer prevention.

On May 7, 2025, Monopar Therapeutics Inc. (NASDAQ:MNPR) presented long-term efficacy and safety data for ALXN1840 (tiomolybdate choline). The data supported ALXN1840 as a potential treatment for Wilson disease. Pooled results from 3 clinical trials (n=255) exhibited sustained clinical benefits over a median treatment duration of 2.63 years. Monopar Therapeutics Inc. (NASDAQ:MNPR), in collaboration with Excel Diagnostics and Nuclear Oncology Center (EDNOC), announced that the physician-sponsored Expanded Access Program (EAP) for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu has received authorization to proceed from the US FDA.

While we acknowledge the potential of MNPR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MNPR and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Cheap AI Stocks to Buy According to Analysts and 11 Unstoppable Growth Stocks to Invest in Now

Disclosure: None.